Here's a stock where the outcome is refreshingly binary: Avalo Therapeutics Inc. (AVTX) either works or it doesn't, and the market will respond accordingly. The company just wrapped up enrollment for its Phase 2 LOTUS trial testing AVTX-009, their lead drug candidate, in about 250 adults with moderate to severe hidradenitis suppurativa. Results are expected mid-2026, and Cantor has mapped out what could happen next—and it's quite the range.

The Bull and Bear Scenarios

Cantor hosted Avalo's management team recently and came away with a framework that's both exciting and sobering. If the trial fails, the stock could plunge 85-90%. That's the bear case, and it's ugly.

But here's where it gets interesting. Analyst Prakhar Agarwal sees upside potential even if the HiSCR75 change lands around 18-19%, though he notes the gains would be capped since some investors might view the Phase 3 trial as risky due to potential efficacy degradation between phases.

For context, HiSCR75—Hidradenitis Suppurativa Clinical Response 75—means a 75% or greater reduction in total abscess and inflammatory nodule count from baseline, with no increase in abscesses or draining tunnels. It's the key metric everyone will be watching.

If AVTX-009 delivers HiSCR75 changes between 20-25%, Avalo's stock could rally 100-150%. And if the results hit that sweet spot of 25-30%? We're talking over 200% upside. That's the kind of asymmetric bet that gets biotech investors excited.

Learning From MoonLake

Cantor pointed to MoonLake Immunotherapeutics (MLTX) as a comparable case study. After Phase 2 data, MoonLake reached a market cap of $2 billion to $2.5 billion—and that happened even when skepticism about the hidradenitis suppurativa market size was running high. The precedent suggests meaningful upside is possible if Avalo's data impresses.

What Management Is Saying

Some investors have expressed concern that Avalo's management might be talking down efficacy expectations for the Phase 2 trial. But Agarwal noted that management actually seemed confident during the meeting. They expect AVTX-009 will show comparable or better results than AbbVie Inc.'s (ABBV) lutikizumab.

The company's competitive edge? Management flagged AVTX-009's superior binding affinity as its biggest advantage, which should translate to stronger IL-1b inhibition that lasts longer.

Worth mentioning: Agarwal cited Novartis AG's (NVS) MAS825, an IL-1b/IL-18 bispecific for hidradenitis suppurativa, as a potential negative for the IL-1b thesis. But Cantor believes the modest efficacy seen with MAS825 might be due to lower potency or underdosing rather than a fundamental problem with the mechanism.

Broader Analyst Sentiment

Cantor maintained its Overweight rating on Avalo, and they're not alone in their optimism. The stock has seen a wave of positive analyst coverage recently. Guggenheim initiated coverage on February 2 with a $50 price target—the highest target set in recent months and a decidedly bullish stance.

HC Wainwright & Co. reiterated a Buy rating on January 15, maintaining a $25 target that was originally established in September. Mizuho initiated coverage in December with an Outperform rating and a $39 target, while BTIG reiterated its Buy rating on September 29 with a $40 target.

Recent Performance

Despite the bullish analyst ratings, Avalo's stock hasn't exactly been thriving. Agarwal noted that the stock has underperformed compared to the State Street SPDR S&P Biotech ETF (XBI), which has gained 2% over the same period. Year-to-date, Avalo's shares have fallen roughly 13%.

At last check on Monday, AVTX stock was trading up 4.57% at $15.80. That's a long way from those $50 price targets, which means there's either enormous upside ahead or analysts are going to have some explaining to do come mid-2026.